BMO Capital Markets Issues Pessimistic Forecast for Omada Health (NASDAQ:OMDA) Stock Price

Omada Health (NASDAQ:OMDA) had its price objective reduced by equities research analysts at BMO Capital Markets from $27.00 to $18.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ target price suggests a potential upside of 28.11% from the stock’s previous close.

Several other research firms have also recently issued reports on OMDA. Weiss Ratings reiterated a “sell (d)” rating on shares of Omada Health in a research report on Thursday, January 22nd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $26.00 price target on shares of Omada Health in a research note on Friday, January 16th. Wells Fargo & Company began coverage on shares of Omada Health in a report on Thursday, January 8th. They issued an “equal weight” rating and a $17.00 price target for the company. Morgan Stanley reduced their price objective on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of Omada Health in a report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.90.

Omada Health Trading Up 3.3%

NASDAQ OMDA opened at $14.05 on Friday. The stock has a market capitalization of $813.61 million and a price-to-earnings ratio of -56.20. The business’s 50 day moving average is $14.03 and its two-hundred day moving average is $18.67. Omada Health has a 12-month low of $10.28 and a 12-month high of $28.40.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.12. The business had revenue of $75.85 million during the quarter.

Insiders Place Their Bets

In other Omada Health news, President Wei-Li Shao sold 5,618 shares of the company’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $16.13, for a total value of $90,618.34. Following the sale, the president owned 69,079 shares of the company’s stock, valued at approximately $1,114,244.27. This represents a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sean P. Duffy sold 40,796 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $15.95, for a total value of $650,696.20. Following the completion of the transaction, the chief executive officer owned 126,644 shares of the company’s stock, valued at approximately $2,019,971.80. This represents a 24.36% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 276,893 shares of company stock worth $4,336,787.

Hedge Funds Weigh In On Omada Health

Hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Omada Health during the fourth quarter worth about $297,000. Utah Retirement Systems acquired a new stake in shares of Omada Health in the fourth quarter valued at approximately $1,237,000. VARCOV Co. purchased a new position in shares of Omada Health during the 4th quarter worth approximately $504,000. Voloridge Investment Management LLC purchased a new position in shares of Omada Health during the 4th quarter worth approximately $2,590,000. Finally, Tudor Investment Corp ET AL raised its position in shares of Omada Health by 373.7% during the 4th quarter. Tudor Investment Corp ET AL now owns 211,416 shares of the company’s stock worth $3,336,000 after purchasing an additional 166,783 shares during the last quarter.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.